Pundits had more to debate than the U.S. reimbursement prospects for Vertex Pharmaceuticals Inc.'s cystic fibrosis (CF) drug Symdeko (tezacaftor/ivacaftor and ivacaftor), cleared by regulators just as the company halted phase III trials in France with a triple-combo CF prospect because a deal couldn't be reached there on reimbursement for another Vertex therapy, Orkambi (lumacaftor/ivacaftor). Read More
NEW YORK – The double-digit reduction in the corporate tax rate and the repatriation provision included in the tax code changes signed into law late last year were hailed as boons for the U.S. biopharma sector, with many pundits predicting that 2018 will finally bring a much-anticipated M&A frenzy. Read More
Consider it the fulfillment of President Donald Trump's campaign promise to bring down drug prices in the U.S. That's how White House Budget Director Mick Mulvaney framed the administration's proposal to give the FDA a hefty spending hike in fiscal 2019 through user fees and tax dollars. Read More
Bioxcel Therapeutics Inc., a company using artificial intelligence to repurpose existing compounds for new uses, has filed to raise up to $69 million in an initial public offering intended to help it advance two candidates through proof of concept (POC), and possibly further. Read More
Researchers have identified a new target that reduced asthma symptoms in mice without the major shortcomings of current therapy, namely, immunosuppression and desensitization. Read More
Scythian Biosciences Corp., of Toronto, said it closed its bought deal short form prospectus offering, including the full exercise of an overallotment option. In total, 772,943 units were sold at $18.60 apiece for gross proceeds of C$14.37 million (US$11.4 million). Read More
Actinium Pharmaceuticals Inc., of New York, said it submitted an FDA investigational new drug application for Actimab-A in combination with CLAG-M to treat relapsed or refractory acute myeloid leukemia (AML) patients. Read More
Trovagene Inc., of San Diego, added two more sites to its phase Ib/II trial testing PCM-075 in combination with either low-dose cytarabine or decitabine in patients with acute myeloid leukemia. Read More
